[1]
|
M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 2, 2005, pp. 74-108.
doi:10.3322/canjclin.55.2.74
|
[2]
|
L.-C. Horn, U. Fischer, G. Raptis, K. Bilek and B. Hentschel, “Tumor Size Is of Prognostic Value in Surgically Treated FIGO Stage II Cervical Cancer,” Gynecologic Oncology, Vol. 107, No. 2, 2007, pp. 310-315.
doi:10.1016/j.ygyno.2007.06.026
|
[3]
|
C. A. Perez, P. W. Grigsby, K. S. Chao, D. G. Mutch and M. A. Lockett, “Tumor Size, Irradiation Dose, and Long-Term Outcome of Carcinoma of Uterine Cervix,” International Journal of Radiation Oncology, Biology, Physics, Vol. 41, No. 2, 1998, pp. 307-317.
doi:10.1016/S0360-3016(98)00067-4
|
[4]
|
M. Morris, P. J. Eifel, J. Lu, et al., “Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer,” The New England Journal of Medicine, Vol. 340, No. 15, 1999, pp. 1137-1143.
doi:10.1056/NEJM199904153401501
|
[5]
|
H. M. Keys, B. N. Bundy, F. B. Stehman, et al., “Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma,” The New England Journal of Medicine, Vol. 340, No. 15, 1999, pp. 1154-1161.
doi:10.1056/NEJM199904153401503
|
[6]
|
P. G. Rose, B. N. Bundy, E. B. Watkins, et al., “Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer,” The New England Journal of Medicine, Vol. 340, No. 15, 1999, pp. 1144-1153. doi:10.1056/NEJM199904153401502
|
[7]
|
W. A. Peters III, P. Y. Liu, R. Barrett, et al., “Concurrent Chemotherapy and Pelvic Radiation Therapy Compared with Pelvic Radiation Therapy Alone as Adjuvant Therapy after Radical Surgery in High-Risk Early-Stage Cancer of the Cervix,” Journal of Clinical Oncology, Vol. 18, No. 8, 2000, pp. 1606-1613.
doi:10.1097/00006254-200008000-00017
|
[8]
|
K. Shibata, F. Kikkawa, Y. Suzuki, et al., “Usefulness of Preoperative Chemoradiation in Locally Advanced Cervical Carcinoma,” Gynecologic and Obstetric Investigation, Vol. 57, No. 2, 2004, pp. 93-99.
doi:10.1159/000075385
|
[9]
|
C. W. Whitney, W. Sause, B. N. Bundy, et al., “A Randomized Comparison of Fluorouracil Plus Cisplatin versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix with Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study,” Journal of Clinical Oncology, Vol. 17, No. 5, 1999, pp. 1339-1348.
|
[10]
|
R. Pearcey, M. Brundage, P. Drouin, et al., “Phase III Trial Comparing Radical Radiotherapy with and without Cisplatin Chemotherapy in Patients with Advanced Squamous Cell Cancer of the Cervix,” Journal of Clinical Oncology, Vol. 20, No. 4, 2002, pp. 966-972.
doi:10.1200/JCO.20.4.966
|
[11]
|
R. S. Lavey, P. Y. Liu, B. E. Greer, et al., “Recombinant Human Erythropoietin as an Adjunct to Radiation Therapy and Cisplatin for Stage IIB-IVA Carcinoma of the Cervix: A Southwest Oncology Group Study,” Gynecologic Oncology, Vol. 95, No. 1, 2004, pp. 145-151.
doi:10.1016/j.ygyno.2004.07.009
|
[12]
|
P. W. Grigsby, M. L. Vest and C. A. Perez, “Recurrent Carcinoma of the Cervix Exclusively in the Paraaortic Nodes Following Radiation Therapy,” International Journal of Radiation Oncology, Biology, Physics, Vol. 28, No. 2, 1994, pp. 451-455.
doi:10.1016/0360-3016(94)90070-1
|
[13]
|
H.-H. Chou, C.-C. Wang, C.-H. Lai, et al., “Isolated Paraaortic Lymph Node Recurrence after Definitive Irradiation for Cervical Carcinoma,” International Journal of Radiation Oncology, Biology, Physics, Vol. 51, No. 2, 2001, pp. 442-448. doi:10.1016/S0360-3016(01)01628-5
|
[14]
|
S. M. Yoon, K. H. Shin, J.-Y. Kim, et al., “The Clinical Values of Squamous Cell Carcinoma Antigen and Carcinoembryonic Antigen in Patients with Cervical Cancer Treated with Concurrent Chemoradiotherapy,” International Journal of Gynecological Cancer, Vol. 17, No. 4, 2007, pp. 872-878.
doi:10.1111/j.1525-1438.2007.00878.x
|
[15]
|
A. Gadducci, R. Tana, A. Fanucchi and A. R. Genazzani, “Biochemical Prognostic Factors and Risk of Relapses in Patients with Cervical Cancer,” Gynecologic Oncology, Vol. 107, No. 1, 2007, pp. S23-S26.
doi:10.1016/j.ygyno.2007.07.033
|
[16]
|
M. Hirakawa, Y. Nagai, M. Inamine, et al., “Predictive Factor of Distant Recurrence in Locally Advanced Squamous Cell Carcinoma of the Cervix Treated with Concurrent Chemoradiotherapy,” Gynecologic Oncology, Vol. 108, No. 1, 2008, pp. 126-129.
doi:10.1016/j.ygyno.2007.08.091
|